Human health risk assessments for three neuropharmaceutical compounds in surface waters
- 1 April 2008
- journal article
- Published by Elsevier BV in Regulatory Toxicology and Pharmacology
- Vol. 50 (3), 420-427
- https://doi.org/10.1016/j.yrtph.2008.01.014
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Pharmaceuticals: a threat to drinking water?Trends in Biotechnology, 2005
- Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a reviewFood and Chemical Toxicology, 2005
- METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTSDrug Metabolism and Disposition, 2003
- Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?Food and Chemical Toxicology, 2002
- A Human Health Risk Assessment of Pharmaceuticals in the Aquatic EnvironmentHuman and Ecological Risk Assessment: An International Journal, 2002
- Duloxetine in the Treatment of Major Depressive DisorderThe Journal of Clinical Psychiatry, 2002
- Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response StudyPublished by American Academy of Pediatrics (AAP) ,2001
- Using Human Data to Protect the Public's HealthRegulatory Toxicology and Pharmacology, 2001
- Case Studies of Categorical Data-Derived Adjustment FactorsHuman and Ecological Risk Assessment: An International Journal, 2001
- An improved model for predicting the fate of consumer product chemicals in wastewater treatment plantsWater Research, 1993